Given the unmet need for improving chemoimmunotherapy in MSS CRC and the established clinical safety of PRMT5 inhibitors, we focused on PRMT5 targeting based on Phase II clinical trials‐proven efficacy of GSK3326595 in both hematologic and solid malignancies.[22] However, the potential of PRMT5i in combination with chemotherapeutic agents and its underlying mechanisms in MSS CRC remain unexplored. Here, PRMT5 is linked to colorectal carcinoma.